about
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyMicroarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinomaPharmGKB: the Pharmacogenomics Knowledge Base.Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancerUsing Drosophila melanogaster to identify chemotherapy toxicity genes.Genomic landscape of metastatic colorectal cancer.Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcomaTranslesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy.Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translationGenetic variability of DNA repair mechanisms influences treatment outcome of gastric cancer.A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancerGenome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations.SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.Genetic polymorphisms in ERCC1 and ERCC2 genes are associated with response to chemotherapy in osteosarcoma patients among Chinese population: a meta-analysis.Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy.Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.The impact of pharmacokinetic gene profiles across human cancers.Association between common polymorphisms in ERCC gene and prognosis of osteosarcoma in patients treated with chemotherapy: a meta-analysis.
P2860
Q26851060-505CCDF6-081C-42D7-9EA4-9435002E65E7Q28116304-0C1AFEEE-15B7-446F-A0C8-779A076202FAQ33855594-DD4BC2D6-056C-46E3-B253-809217578DCCQ34050097-9399F53C-27DD-4052-B4DD-DCAFF176CD8CQ34242959-540F281A-45D8-4EC6-951C-025C5125B613Q34568317-9A46C016-1D1F-4A01-858A-AC0A2A5F9506Q35144919-65581AAD-8260-498A-8B21-FF9282D37F4AQ35167370-E0617032-56EE-4634-AAAC-2BEC57833DFEQ35196480-725720CE-4018-4EA3-83FD-073E2EE3F8C8Q35799841-F8C9C6D7-1CAF-47D8-B3B6-F5B040ECDC19Q36085389-08CB20C7-1974-4C34-A10B-81659A522D55Q36447729-3DD902A8-A8F6-4C20-9D89-F6C16A97A5C0Q37233810-D7B34584-4668-4523-9323-2A31C1EF5EE8Q38835268-DA8B2AD2-45E5-4DF8-8F47-F4B2316DF97FQ39008172-CBCABD8B-9CCC-40B1-9CE6-DAB97680130DQ39489732-98928038-0271-47DA-8DCD-C78399A0B64BQ40936032-F657C4B3-1D36-41F6-8C06-35254F6145A7Q42090447-97EBF651-4E60-4D5B-A375-B165B95F03B6Q48259649-919F843D-4F54-41A2-9F96-F25B242AF283Q52980012-A6A4BA44-1942-4DC1-A717-55C5CEE226DBQ55294975-2D00CB2C-14FB-4BEB-8770-C2EAC8A70E0FQ55313372-FC43E25E-E0F8-4CE0-993C-3EAB13E4D37E
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Platinum pathway.
@en
type
label
Platinum pathway.
@en
prefLabel
Platinum pathway.
@en
P2093
P2860
P1476
Platinum pathway.
@en
P2093
Eileen Dolan
Howard McLeod
Sharon Marsh
Sunita J Shukla
Teri E Klein
Tina Hernandez-Boussard
Xing Jian Lou
P2860
P304
P356
10.1097/FPC.0B013E32832E0ED7
P577
2009-07-01T00:00:00Z